motexafin gadolinium + 5-fluorouracil + cisplatin

**Motexafin gadolinium + 5-fluorouracil + cisplatin** is a combination regimen comprised of motexafin gadolinium, a redox-active, tumor-selective porphyrin-like molecule that disrupts cancer cell redox metabolism and induces apoptosis; 5-fluorouracil (5-FU), a pyrimidine analog that inhibits thymidylate synthase, causing DNA damage and cell death; and cisplatin, a platinum-based chemotherapeutic that crosslinks DNA, leading to apoptosis. Motexafin gadolinium preferentially accumulates in tumor cells and enhances the activity of radiation and certain chemotherapy drugs. This combination is evaluated for potential synergistic antitumor efficacy in clinical trials, with motexafin gadolinium acting as both a direct cytotoxic agent and a chemotherapy sensitizer[1][2].

Other names

motexafin gadolinium5-FUcisplatin